Similar articles

• [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].

  Fitscha P, Simmet T, Peskar BA, Reuter H, Sinzinger H, Rogatti W, Tilsner V. Fitscha P, et al. Wien Klin Wochenschr. 1988 Jul 15;100(14):477-81. Wien Klin Wochenschr. 1988. PMID: 3062905 Clinical Trial. German.
• [Pharmacologic concepts for clinical use of prostaglandin E1].

  Schrör K. Schrör K. Vasa Suppl. 1991;33:335-6. Vasa Suppl. 1991. PMID: 1788746 Review. German.
• [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].

  Sinzinger H, Rogatti W. Sinzinger H, et al. Wien Klin Wochenschr. 1991;103(18):558-65. Wien Klin Wochenschr. 1991. PMID: 1750223 Review. German.
• The effect of parenteral lipid emulsion-induced hyperlipidemia on prostaglandin E1 modulation of platelet function.

  Saladino CF, Kosacolsky-Singer C, Fox R, Nethala V, Feffer SE, Jonas EA. Saladino CF, et al. Artery. 1993;20(6):303-13. Artery. 1993. PMID: 8010886
• [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].

  Hesse WH, Rudofsky G, Peskar BA. Hesse WH, et al. Wien Klin Wochenschr. 1991;103(18):554-7. Wien Klin Wochenschr. 1991. PMID: 1750222 German.